Vasculitis during certolizumab pegol and secukinumab treatment: Report of two cases.

Bostan, Ecem; Gulseren, Duygu; Yalici-Armagan, Basak; Dogan, Sibel; Ates-Ozdemir, Deniz; Gokoz, Ozay; Kalyoncu, Umut; Atakan, Nilgün

Bostan, Ecem; Gulseren, Duygu; Yalici-Armagan, Basak; Dogan, Sibel; Ates-Ozdemir, Deniz; Gokoz, Ozay; Kalyoncu, Umut; Atakan, Nilgün.

Afiliação

Bostan E; Department of Dermatology and Venereology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Gulseren D; Department of Dermatology and Venereology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Yalici-Armagan B; Department of Dermatology and Venereology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Dogan S; Department of Dermatology and Venereology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Ates-Ozdemir D; Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Gokoz O; Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Kalyoncu U; Department of Rheumatology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Atakan N; Department of Dermatology and Venereology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Dermatol Ther ; 34(4): e15007, 2021 07.

Article em En | MEDLINE | ID: mdl-34046982

Assuntos

Antirreumáticos; Vasculite; Anticorpos Monoclonais Humanizados; Certolizumab Pegol/efeitos adversos; Humanos; Resultado do Tratamento; Fator de Necrose Tumoral alfa

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vasculite / Antirreumáticos Limite: Humans Idioma: En Revista: Dermatol Ther Assunto da revista: DERMATOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Turquia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google